PMID- 18753057
OWN - NLM
STAT- MEDLINE
DCOM- 20090331
LR  - 20151119
IS  - 1673-4254 (Print)
IS  - 1673-4254 (Linking)
VI  - 28
IP  - 8
DP  - 2008 Aug
TI  - [Clinical study of etanercept for treating ankylosing spondylitis].
PG  - 1349-51
AB  - OBJECTIVE: To evaluate the efficacy and safety of etanercept, a tumor necrosis 
      factor (TNF)-alpha inhibitor, in the treatment of ankylosing spondylitis (AS), 
      and investigate its effect on serum levels of matrix metalloproteinase-3 (MMP-3). 
      METHODS: Forty-eight patients with AS received etanercept 25 mg twice a week for 
      a treatment course of 12 weeks. The patients' symptoms, signs, Bath Ankylosing 
      Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis 
      Functional Index (BASFI), erythrocyte sedimentation rate (ESR), C-reactive 
      protein (CRP) levels and side effects were observed before and after the 
      treatment. The serum levels of MMP-3 was determined using enzyme-linked 
      immunosorbent assay (ELISA). RESULTS: All the patients completed the treatment. 
      The degree of spinal pain and pain at night, the duration of morning stiffness, 
      the finger-to-floor distance, BASDAI and BASFI were significantly improved after 
      the treatment (P<0.05). Etanercept treatment resulted in a significant reduction 
      in serum MMP-3 level in the AS patients to 31.22-/+10.26 ng/ml as compared with 
      the level before treatment (46.17-/+25.74 ng/ml, P<0.05). The reduction of serum 
      MMP-3 was positively correlated to decrement of ESR and CRP (r=0.397 and 0.474, 
      respectively, P<0.05). The most common adverse events of etanercept included 
      injection site reaction and upper respiratory infection. CONCLUSION: Etanercept 
      treatment has obvious therapeutic effects on AS without serious adverse effects. 
      MMP-3 may be a potentially useful indicator to assess the effect of 
      anti-TNF-alpha treatment in AS patients.
FAU - Liang, Liu-qin
AU  - Liang LQ
AD  - Department of Rheumatology and Clinical Immunology, First Affiliated Hospital of 
      Sun Yat-sen University, Guangzhou, China. lliuq@mail.sysu.edu.cn
FAU - Zhan, Zhong-ping
AU  - Zhan ZP
FAU - Ye, Yu-jin
AU  - Ye YJ
FAU - Fu, Di
AU  - Fu D
FAU - Xu, Han-shi
AU  - Xu HS
FAU - Yang, Xiu-yan
AU  - Yang XY
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - C-Reactive Protein/metabolism
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Spondylitis, Ankylosing/blood/*drug therapy/pathology
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
MH  - Young Adult
EDAT- 2008/08/30 09:00
MHDA- 2009/04/01 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2009/04/01 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1349-51.